Cargando…
Biologics for Psoriasis during the COVID-19 Pandemic
Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are re...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036429/ https://www.ncbi.nlm.nih.gov/pubmed/33808455 http://dx.doi.org/10.3390/jcm10071390 |
_version_ | 1783676908058181632 |
---|---|
author | Kamiya, Koji Komine, Mayumi Ohtsuki, Mamitaro |
author_facet | Kamiya, Koji Komine, Mayumi Ohtsuki, Mamitaro |
author_sort | Kamiya, Koji |
collection | PubMed |
description | Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19. |
format | Online Article Text |
id | pubmed-8036429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80364292021-04-12 Biologics for Psoriasis during the COVID-19 Pandemic Kamiya, Koji Komine, Mayumi Ohtsuki, Mamitaro J Clin Med Review Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19. MDPI 2021-03-30 /pmc/articles/PMC8036429/ /pubmed/33808455 http://dx.doi.org/10.3390/jcm10071390 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kamiya, Koji Komine, Mayumi Ohtsuki, Mamitaro Biologics for Psoriasis during the COVID-19 Pandemic |
title | Biologics for Psoriasis during the COVID-19 Pandemic |
title_full | Biologics for Psoriasis during the COVID-19 Pandemic |
title_fullStr | Biologics for Psoriasis during the COVID-19 Pandemic |
title_full_unstemmed | Biologics for Psoriasis during the COVID-19 Pandemic |
title_short | Biologics for Psoriasis during the COVID-19 Pandemic |
title_sort | biologics for psoriasis during the covid-19 pandemic |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036429/ https://www.ncbi.nlm.nih.gov/pubmed/33808455 http://dx.doi.org/10.3390/jcm10071390 |
work_keys_str_mv | AT kamiyakoji biologicsforpsoriasisduringthecovid19pandemic AT kominemayumi biologicsforpsoriasisduringthecovid19pandemic AT ohtsukimamitaro biologicsforpsoriasisduringthecovid19pandemic |